Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells from Human Mobilized Peripheral Blood for Gene Therapy Applications

This study presents a clinically compliant, optimized ex vivo expansion protocol for mobilized peripheral blood hematopoietic stem cells that maintains stemness and transduction efficiency, as validated by single-cell sequencing and clonal tracking, paving the way for a gene therapy trial in autosomal recessive osteopetrosis.

The Gist

The Big Picture: Saving a Life with a "Seed" Problem

Imagine your body is a massive, bustling city. The Hematopoietic Stem Cells (HSCs) are the master gardeners or "seed packets" that live in your bone marrow. Their job is to constantly grow new trees (red blood cells), flowers (white blood cells), and grass (platelets) to keep the city running.

Sometimes, the city gets sick because the gardeners have a broken instruction manual (a genetic disease). Gene therapy is like giving those gardeners a new, corrected manual. But there's a catch: sometimes, there just aren't enough gardeners to save the whole city, or the ones you have are too tired to do the job.

This paper is about a new, improved way to grow more of these master gardeners in a lab before putting them back into the patient. The goal is to take a small handful of seeds, multiply them into a forest, and ensure they are healthy enough to rebuild the patient's entire blood system.

---

The Challenge: The "Stressful Hotel"

Previously, scientists tried to grow these stem cells in a lab using a standard "recipe" (culture media) that worked well for Umbilical Cord Blood (seeds from a baby's umbilical cord). Think of Cord Blood seeds as eager, fast-growing saplings that love a specific type of hotel room.

However, the scientists needed to use Mobilized Peripheral Blood (mPB) seeds (taken from adults or older children). These are like mature, stubborn oak trees. When you put them in the "Cord Blood Hotel," they get stressed. They try to grow, but they lose their special "master gardener" powers and turn into regular, short-lived workers before they can be used.

The Problem: The more you try to multiply them, the more they lose their magic. Plus, the step of inserting the new gene (gene therapy) acts like a heavy backpack, making them even more tired and stressed.

---

The Solution: Designing a "Luxury Spa" for Adult Seeds

The team at SR-TIGET decided to stop trying to force the adult seeds into the baby seed hotel. Instead, they built a custom "Luxury Spa" specifically for adult stem cells. Here is how they optimized the process, step-by-step:

1. The Right Food and Drink (Cytokines)

Just like humans need specific vitamins, stem cells need specific chemical signals (cytokines) to grow.

• The Discovery: They found that adult seeds didn't like the standard drink. They needed a specific mix of IL-3 and IL-6 (think of these as a special energy drink and a calming tea) to keep them happy and growing without losing their identity.

2. The Right Room (Culture Media)

• The Discovery: They tested different "beds" (culture media). One specific commercial medium (SCGM) acted like a memory foam mattress that kept the seeds comfortable, while others were like sleeping on a rock. The right medium kept the seeds looking like "master gardeners" rather than turning them into regular workers.

3. The Timing of the "Backpack" (Transduction Timing)

This was a major "Aha!" moment.

• The Analogy: Imagine you are trying to teach a student a new skill while they are running a marathon. If you give them the book while they are sprinting, they will trip and fall.
• The Finding: The scientists realized that if they gave the gene therapy vector (the "backpack" with the new instructions) too late in the growth process (after the cell had already started dividing), the cell got overwhelmed and died or stopped working.
• The Fix: They found a "sweet spot" window (between 36 and 48 hours). It's like giving the student the book before the race starts, so they can pack it and run smoothly.

4. What Not to Do (The Toxic Cocktail)

They tried adding a powerful drug called 4HPR (which helps other types of cells) to the mix.

• The Result: It was a disaster. When combined with the gene therapy "backpack," it was like giving the tired gardener a heavy hammer and a backpack. The cells collapsed. They learned that for adult stem cells, less is sometimes more.

---

The Proof: Did the Seeds Work?

To prove their new "Luxury Spa" worked, they did two things:

1. The "Clonal Tracking" (The Family Tree):
   They gave the stem cells unique "barcodes" (like a digital fingerprint). When they put the cells into mice, they checked the blood later.

   • The Result: They saw that the same barcode appeared in different mice. This proved that the cells had divided symmetrically (one gardener became two master gardeners) rather than just growing into regular workers. The "family tree" was healthy and diverse, not dominated by just one clone.

2. The "Second Generation" Test:
   They took the blood from the first group of mice and put it into a second group of mice.

   • The Result: The cells still worked! This is the ultimate test. It means the cells didn't just survive; they kept their "immortality" and ability to rebuild the system over the long term.

The Bottom Line

This paper is a blueprint for a new, safer, and more effective way to treat genetic diseases using gene therapy.

• Before: We tried to grow adult stem cells using baby rules, and they struggled.
• Now: We have a custom protocol that respects the biology of adult cells. We feed them the right food, put them in the right room, and give them their gene therapy at the perfect time.

Why does this matter?
For patients with severe diseases like Osteopetrosis (a condition where bones become too dense and brittle because the body can't break them down), there often aren't enough stem cells to cure them. This new method allows doctors to take a small sample, grow a massive army of corrected cells, and give the patient a much better chance of a full cure.

It's like turning a single seed into a whole forest, ensuring that every tree is strong enough to weather the storm.

Technical Summary

1. Problem Statement

Ex vivo expansion of Hematopoietic Stem and Progenitor Cells (HSPCs) is a critical strategy to overcome limitations in cell availability for gene therapy (GT) and allogeneic transplantation. While expansion protocols for Umbilical Cord Blood (CB) have shown success (e.g., using UM171), their application to Mobilized Peripheral Blood (mPB)—the preferred source for autologous GT—has been limited.

• Key Challenges:
  • Loss of Stemness: Standard culture protocols often induce differentiation, leading to a loss of long-term repopulating HSCs.
  • Gene Therapy Toxicity: The combination of lentiviral (LV) transduction and ex vivo expansion creates cumulative cellular stress, potentially impairing HSC function.
  • Source Differences: mPB HSCs differ biologically from CB HSCs (e.g., cell cycle kinetics, niche dependency), making CB-specific protocols suboptimal.
  • Predictive Gaps: Current in vitro release assays (like Vector Copy Number, VCN) often fail to predict in vivo engraftment and transgene persistence in patients.

2. Methodology

The authors employed a multi-faceted approach combining single-cell genomics, xenotransplantation, and iterative protocol optimization:

• Cell Sources: mPB CD34+ cells from healthy adult donors and pediatric patients enrolled in a gene therapy trial for Mucopolysaccharidosis type I (MPSI-H).
• Single-Cell RNA Sequencing (scRNAseq): Used to map differentiation trajectories, identify HSC clusters, and predict transduction efficiency (via WPRE transcript detection) in real-time.
• Xenotransplantation Models: NSG mice were used for primary and secondary transplantation to assess short-term (ST-HSC) and long-term (LT-HSC) repopulation, multilineage output, and clonal diversity.
• Clonal Tracking: Utilized two methods:
  • Lentiviral Integration Site (LVIS) analysis: To track unique integration sites.
  • Lentiviral Barcode (LVBC) libraries: To quantify clonal abundance and sharing between mice (proving symmetric self-renewal).
• Iterative Optimization: Tested combinations of:
  • Cytokines: SCF, FLT3L, TPO, IL-6, and IL-3.
  • Small Molecules: UM171 (epigenetic modifier), SR1 (AHR antagonist), and 4HPR (sphingolipid/proteostasis modulator).
  • Media: Commercial serum-free media (SCGM) vs. chemically defined media.
  • Transduction Timing: Shifting LV exposure windows (24h, 48h, 72h) relative to culture start.
• GMP Compliance: Final validation was performed using a Good Manufacturing Practice (GMP) compliant process with clinical-grade vectors.

3. Key Contributions

1. Development of an Optimized mPB Expansion Protocol: A clinically translatable, GMP-compliant process that maintains LT-HSC function in mPB, outperforming standard short-culture protocols.
2. Discovery of LV Transduction Toxicity: Identification that LV transduction induces a stress response (senescence/aging pathways) in mPB HSCs, which is exacerbated by specific culture conditions (e.g., 4HPR) and timing.
3. scRNAseq as a Predictive Tool: Demonstrated that scRNAseq of expansion cultures can accurately predict in vivo VCN and transduction efficiency in LT-HSCs, potentially replacing costly xenograft assays for release testing.
4. Proof of Symmetric Self-Renewal: Provided definitive evidence (via barcode sharing and LVIS) that the optimized protocol supports symmetric self-renewal divisions of mPB HSCs ex vivo.

4. Key Results

• Baseline Performance: Initial UM171-based expansion maintained LT-HSC potential but showed reduced net expansion compared to CB. High LV transduction doses (VCN >5) correlated with reduced engraftment in some patients.
• scRNAseq Insights:
  • Expansion cultures primarily expanded committed progenitors while preserving lineage fidelity.
  • A "putative HSC cluster" was identified, allowing the estimation of LV+ cells. This in silico VCN prediction correlated with in vivo xenograft and patient data, explaining why some patients had low in vivo VCN despite high in vitro measurements (due to loss of LV+ HSCs during culture).
• Protocol Optimization Findings:
  • Cytokines: Adding intermediate doses of IL-3 to the standard SFT6 cocktail (SCF, FLT3L, TPO, IL-6) significantly improved expansion and engraftment.
  • Media: SCGM (CellGenix) outperformed other commercial and chemically defined media for mPB expansion.
  • Small Molecules:
    • SR1 (AHR antagonist): Added benefit to UM171, particularly for maintaining LT-HSCs with latency characteristics (improved secondary engraftment).
    • 4HPR: Detrimental. While beneficial for CB, 4HPR caused significant toxicity in mPB HSCs, especially when combined with LV transduction, leading to loss of engraftment.
  • Transduction Timing: The timing of LV exposure is critical. Transduction at 72–96 hours (late) induced senescence and reduced engraftment. The optimal window was 36–48 hours (EX-U2), preserving HSC potency while maintaining high transduction efficiency.
• Final GMP Validation:
  • The optimized protocol (SFT63 + UM171 + SR1, transduction at 36–48h) produced expanded products with higher VCN per genome and greater clonal diversity compared to standard short-culture controls (DP-like), even at lower transplant cell doses.
  • Symmetric Division: Clonal tracking confirmed that expanded cells underwent symmetric self-renewal, evidenced by shared barcodes/LVIS across multiple recipient mice.

5. Significance

• Clinical Translation: This work provides a validated, GMP-compliant expansion protocol specifically tailored for mPB HSCs, addressing a major bottleneck in autologous gene therapy for pediatric and adult patients with low cell yields.
• Safety and Efficacy: By optimizing transduction timing and avoiding toxic combinations (like 4HPR + LV), the protocol minimizes the risk of clonal dominance and preserves the polyclonal nature of the graft, which is crucial for long-term safety.
• New Disease Target: The protocol is being implemented in an upcoming Phase I/II clinical trial (EU CT 2024-518972-30) for Autosomal Recessive Osteopetrosis (ARO), a severe disorder where rapid myeloid reconstitution is critical.
• Methodological Advance: The study establishes scRNAseq as a powerful surrogate for in vivo functional assays, potentially streamlining the manufacturing and release testing of future gene therapies.

In summary, the authors successfully bridged the gap between experimental expansion protocols and clinical application for mPB, creating a robust process that enhances the therapeutic potential of gene-corrected HSCs while mitigating the specific stressors associated with lentiviral engineering.